



# Interpretation of Z drugs-Zaleplon, Zolpidem, Zopiclone Impairment Cases: What You Should Be Reading Bibliography

## Literature:

Hoffmann, F., M. Pfannkuche, et al. (2008). "[High usage of zolpidem and zopiclone : Cross-sectional study using claims data.]." Nervenarzt 79(1): 67-72.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=17457554](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17457554)

[Gustavsen, I., J. G. Bramness, et al. \(2008\). "Road traffic accident risk related to prescriptions of the hypnotics zopiclone, zolpidem, flunitrazepam and nitrazepam." Sleep Med.](#)

Farber, R. H. and P. J. Burke (2008). "Post-bedtime dosing with indiplon in adults and the elderly: results from two placebo-controlled, active comparator crossover studies in healthy volunteers." Curr Med Res Opin. [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=18257978](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18257978)

Deveaux, M., M. Cheze, et al. (2008). "The Role of Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) to Test Blood and Urine Samples for the Toxicological Investigation of Drug-Facilitated Crimes." Ther Drug Monit 30(2): 225-8. [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=18367985](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18367985)

Sancar, F., S. S. Ericksen, et al. (2007). "Structural determinants for high-affinity zolpidem binding to GABA-A receptors." Mol Pharmacol 71(1): 38-46. [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=17012619](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17012619)

Roth, T., D. Mayleben, et al. (2007). "Daytime pharmacodynamic and pharmacokinetic evaluation of low-dose sublingual transmucosal zolpidem hemitartrate." Hum Psychopharmacol. [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=17907263](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17907263)

Oiestad, E. L., U. Johansen, et al. (2007). "Drug screening of preserved oral

# **Interpretation of Z drugs-Zaleplon, Zolpidem, Zopiclone Impairment Cases: What You Should Be Reading Bibliography**

fluid by liquid chromatography-tandem mass spectrometry." Clin Chem 53(2): 300-9.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=17158196](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17158196)

Moloney, I., E. G. Breen, et al. (2007). "**Extreme agitation occurring with zopiclone.**" Ir Med J 100(6): 511.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=17668690](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17668690)

Mayer, A. R., A. R. Franco, et al. (2007). "**Assessment and quantification of head motion in neuropsychiatric functional imaging research as applied to schizophrenia.**" J Int Neuropsychol Soc 13(5): 839-45.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=17697415](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17697415)

Mathiasen, L. S., R. J. Rodgers, et al. (2007). "**Comparative effects of nonselective and subtype-selective gamma-aminobutyric acidA receptor positive modulators in the rat-conditioned emotional response test.**" Behav Pharmacol 18(3): 191-203.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=17426483](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17426483)

Lovett, B., D. Watts, et al. (2007). "**Prolonged coma after eszopiclone overdose.**" Am J Emerg Med 25(6): 735 e5-6.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=17606111](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17606111)

Lewis, J. H. and J. H. Vine (2007). "**A simple and rapid method for the identification of zolpidem carboxylic acid in urine.**" J Anal Toxicol 31(4): 195-9.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=17555642](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17555642)

Kintz, P. (2007). "**Bioanalytical procedures for detection of chemical agents in hair in the case of drug-facilitated crimes.**" Anal Bioanal Chem 388(7): 1467-74.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=17555642](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17555642)

# **Interpretation of Z drugs-Zaleplon, Zolpidem, Zopiclone Impairment Cases: What You Should Be Reading Bibliography**

opt=Citation&list\_uids=17340077

Jones, A. W., A. Holmgren, et al. (2007). "**Concentrations of scheduled prescription drugs in blood of impaired drivers: considerations for interpreting the results.**" Ther Drug Monit 29(2): 248-60.  
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=17417081](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17417081)

Ito, S. U., T. Kanbayashi, et al. (2007). "**Acute effects of zolpidem on daytime alertness, psychomotor and physical performance.**" Neurosci Res 59(3): 309-13.  
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=17825448](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17825448)

Gaillard, R., A. Hemras, et al. (2007). "**Cognitive facilitation and behavioral disinhibition with benzodiazepine: a case report.**" J Clin Psychiatry 68(8): 1305-6.  
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=17854259](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17854259)

Dolder, C., M. Nelson, et al. (2007). "**Use of non-benzodiazepine hypnotics in the elderly: are all agents the same?"** CNS Drugs 21(5): 389-405.  
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=17447827](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17447827)

Cysneiros, R. M., D. Farkas, et al. (2007). "**Pharmacokinetic and pharmacodynamic interactions between zolpidem and caffeine.**" Clin Pharmacol Ther 82(1): 54-62.  
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=17443132](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17443132)

Cranwell-Bruce, L. A. (2007). "**Hypnotic sedative drugs.**" Medsurg Nurs 16(3): 198-200.  
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=17849930](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17849930)

Bloetzer, C., A. Carota, et al. (2007). "**Zopiclone Intoxication: Value of Electroencephalography in the Emergency Room.**" Eur Neurol 58(4): 246-

# **Interpretation of Z drugs-Zaleplon, Zolpidem, Zopiclone Impairment Cases: What You Should Be Reading Bibliography**

247.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=17851247](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17851247)

**Bhatt, J., G. Subbaiah, et al. (2007). "A rapid and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the estimation of rivastigmine in human plasma." J Chromatogr B Analyt Technol Biomed Life Sci 852(1-2): 115-21.**

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=17296337](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17296337)

**Barkin, R. L. (2007). "Zolpidem extended-release: a single insomnia treatment option for sleep induction and sleep maintenance symptoms." Am J Ther 14(3): 299-305.**

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=17515707](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17515707)

**(2007). "Putting "sleepdriving" and new safety warning in perspective." Johns Hopkins Med Lett Health After 50 19(6): 1-2.**

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=17712908](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17712908)

**Zhang, B., Z. Zhang, et al. (2006). "High-performance liquid chromatography-atmospheric pressure chemical ionisation-mass spectrometry determination of zaleplon in human plasma." J Pharm Biomed Anal 40(3): 707-14.**

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=16087308](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16087308)

**Sherker, S., C. Finch, et al. (2006). "Drunk, drowsy, doped: skiers' and snowboarders' injury risk perceptions regarding alcohol, fatigue and recreational drug use." Int J Inj Contr Saf Promot 13(3): 151-7.**

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=16943158](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16943158)

**Roth, T., C. Soubrane, et al. (2006). "Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia." Sleep Med 7(5): 397-406.**

# **Interpretation of Z drugs-Zaleplon, Zolpidem, Zopiclone Impairment Cases: What You Should Be Reading Bibliography**

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=16815744](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16815744)

Quintela, O., F. L. Sauvage, et al. (2006). "**Liquid chromatography-tandem mass spectrometry for detection of low concentrations of 21 benzodiazepines, metabolites, and analogs in urine: method with forensic applications.**" Clin Chem 52(7): 1346-55.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=16709625](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16709625)

Petroski, R. E., J. E. Pomeroy, et al. (2006). "**Indiplon is a high-affinity positive allosteric modulator with selectivity for alpha1 subunit-containing GABAA receptors.**" J Pharmacol Exp Ther 317(1): 369-77.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=16399882](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16399882)

Patil, P. A. and M. A. Kothekar (2006). "**Development of safer molecules through chirality.**" Indian J Med Sci 60(10): 427-37.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=17006031](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17006031)

Pandi-Perumal, S. R., J. C. Verster, et al. (2006). "**Sleep disorders, sleepiness and traffic safety: a public health menace.**" Braz J Med Biol Res 39(7): 863-71.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=16862276](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16862276)

Owen, R. T. (2006). "**Extended-release zolpidem: efficacy and tolerability profile.**" Drugs Today (Barc) 42(11): 721-7.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=17171191](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17171191)

Nirogi, R. V., V. N. Kandikere, et al. (2006). "**Quantification of zolpidem in human plasma by high-performance liquid chromatography with fluorescence detection.**" Biomed Chromatogr 20(10): 1103-8.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=16703647](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16703647)

# **Interpretation of Z drugs-Zaleplon, Zolpidem, Zopiclone Impairment Cases: What You Should Be Reading Bibliography**

Najib, J. (2006). "Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia." Clin Ther 28(4): 491-516.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=16750462](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16750462)

Moen, M. D. and G. L. Plosker (2006). "Zolpidem extended-release." CNS Drugs 20(5): 419-26; discussion 427-8.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=16696581](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16696581)

Miyaguchi, H., K. Kuwayama, et al. (2006). "A method for screening for various sedative-hypnotics in serum by liquid chromatography/single quadrupole mass spectrometry." Forensic Sci Int 157(1): 57-70.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=15869852](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15869852)

Mellingsaeter, T. C., J. G. Bramness, et al. (2006). "[Are z-hypnotics better and safer sleeping pills than benzodiazepines?]." Tidsskr Nor Laegeforen 126(22): 2954-6.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=17117195](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17117195)

Hindmarch, I., E. Legangneux, et al. (2006). "A double-blind, placebo-controlled investigation of the residual psychomotor and cognitive effects of zolpidem-MR in healthy elderly volunteers." Br J Clin Pharmacol 62(5): 538-45.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=17061961](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17061961)

Halas, C. J. (2006). "Eszopiclone." Am J Health Syst Pharm 63(1): 41-8.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=16373464](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16373464)

Greenblatt, D. J., E. Legangneux, et al. (2006). "Dynamics and kinetics of a modified-release formulation of zolpidem: comparison with immediate-release standard zolpidem and placebo." J Clin Pharmacol 46(12): 1469-80.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=17061961](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17061961)

# Interpretation of Z drugs-Zaleplon, Zolpidem, Zopiclone Impairment Cases: What You Should Be Reading Bibliography

opt=Citation&list\_uids=17101746

Fahey, J. M., J. M. Grassi, et al. (2006). "**Acute zolpidem administration produces pharmacodynamic and receptor occupancy changes at similar doses.**" Pharmacol Biochem Behav 83(1): 21-7.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=16439007](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16439007)

Djezzar, S., J. Dugarin, et al. (2006). "**Zolpidem and dextromoramide abuse with increased metabolism.**" Am J Addict 15(5): 405-6.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=16966202](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16966202)

Yasui, M., A. Kato, et al. (2005). "**[Pharmacological profiles of benzodiazepinergic hypnotics and correlations with receptor subtypes].**" Nihon Shinkei Seishin Yakurigaku Zasshi 25(3): 143-51.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=16045197](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16045197)

Wynn, R. L. and S. A. Bergman (2005). "**The new Z-drugs as sedatives and hypnotics.**" Gen Dent 53(3): 174-7.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=15960472](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15960472)

Wesensten, N. J., T. J. Balkin, et al. (2005). "**Daytime sleep and performance following a zolpidem and melatonin cocktail.**" Sleep 28(1): 93-103.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=15700725](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15700725)

Swainston Harrison, T. and G. M. Keating (2005). "**Zolpidem: a review of its use in the management of insomnia.**" CNS Drugs 19(1): 65-89.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=15651908](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15651908)

Stepanski, E. J. (2005). "**Hypnotics should not be considered for the initial treatment of chronic insomnia. Con.**" J Clin Sleep Med 1(2): 125-8.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=15651908](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15651908)

# **Interpretation of Z drugs-Zaleplon, Zolpidem, Zopiclone Impairment Cases: What You Should Be Reading Bibliography**

opt=Citation&list\_uids=17561624

Staner, L., S. Ertle, et al. (2005). "Next-day residual effects of hypnotics in DSM-IV primary insomnia: a driving simulator study with simultaneous electroencephalogram monitoring." Psychopharmacology (Berl) 181(4): 790-8.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=16025317](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16025317)

Nordgren, H. K., P. Holmgren, et al. (2005). "Application of direct urine LC-MS-MS analysis for screening of novel substances in drug abusers." J Anal Toxicol 29(4): 234-9.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=15975252](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15975252)

Melton, S. T., J. M. Wood, et al. (2005). "Eszopiclone for insomnia." Ann Pharmacother 39(10): 1659-66.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=16131537](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16131537)

Laloup, M., M. Ramirez Fernandez Mdel, et al. (2005). "Validation of a liquid chromatography-tandem mass spectrometry method for the simultaneous determination of 26 benzodiazepines and metabolites, zolpidem and zopiclone, in blood, urine, and hair." J Anal Toxicol 29(7): 616-26.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=16419390](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16419390)

Kintz, P., M. Villain, et al. (2005). "Drug-facilitated sexual assault and analytical toxicology: the role of LC-MS/MS A case involving zolpidem." J Clin Forensic Med 12(1): 36-41.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=15763689](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15763689)

Kintz, P., M. Villain, et al. (2005). "Screening and confirmatory method for benzodiazepines and hypnotics in oral fluid by LC-MS/MS." Forensic Sci Int 150(2-3): 213-20.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=15944062](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15944062)

# Interpretation of Z drugs-Zaleplon, Zolpidem, Zopiclone Impairment Cases: What You Should Be Reading Bibliography

Allain, H., D. Bentue-Ferrer, et al. (2005). "Postural instability and consequent falls and hip fractures associated with use of hypnotics in the elderly: a comparative review." Drugs Aging 22(9): 749-65.  
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=16156679](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16156679)

(2005). "Eszopiclone: esopiclone, estorra, S-zopiclone, zopiclone-- Sepracor." Drugs R D 6(2): 111-5.  
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=15777104](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15777104)

(2005). "Eszopiclone (Lunesta), a new hypnotic." Obstet Gynecol 106(2): 398-401.  
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=16055594](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16055594)

(2005). "Ambien CR for insomnia." Med Lett Drugs Ther 47(1223-1224): 97-8.  
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=16331242](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16331242)

(2005). "Eszopiclone (Lunesta), a new hypnotic." Med Lett Drugs Ther 47(1203): 17-9.  
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=15767972](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15767972)

Zammit, G. K., L. J. McNabb, et al. (2004). "Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia." Curr Med Res Opin 20(12): 1979-91.  
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=15701215](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15701215)

Verster, J. C., D. S. Veldhuijzen, et al. (2004). "Residual effects of sleep medication on driving ability." Sleep Med Rev 8(4): 309-25.  
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=15233958](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15233958)

Vermeeren, A. (2004). "Residual effects of hypnotics: epidemiology and

# **Interpretation of Z drugs-Zaleplon, Zolpidem, Zopiclone Impairment Cases: What You Should Be Reading Bibliography**

clinical implications." CNS Drugs 18(5): 297-328.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=15089115](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15089115)

Sanger, D. J. (2004). "The pharmacology and mechanisms of action of new generation, non-benzodiazepine hypnotic agents." CNS Drugs 18 Suppl 1: 9-15; discussion 41, 43-5.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=15291009](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15291009)

Pompeia, S., L. M. Lucchesi, et al. (2004). "Zolpidem and memory: a study using the process-dissociation procedure." Psychopharmacology (Berl) 174(3): 327-33.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=14985932](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14985932)

Noguchi, H., K. Kitazumi, et al. (2004). "Electroencephalographic properties of zaleplon, a non-benzodiazepine sedative/hypnotic, in rats." J Pharmacol Sci 94(3): 246-51.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=15037809](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15037809)

Marrache, F., B. Megarbane, et al. (2004). "Difficulties in assessing brain death in a case of benzodiazepine poisoning with persistent cerebral blood flow." Hum Exp Toxicol 23(10): 503-5.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=15553176](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15553176)

Mahoney, J. E., M. J. Webb, et al. (2004). "Zolpidem prescribing and adverse drug reactions in hospitalized general medicine patients at a Veterans Affairs hospital." Am J Geriatr Pharmacother 2(1): 66-74.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=15555480](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15555480)

Kratzsch, C., O. Tenberken, et al. (2004). "Screening, library-assisted identification and validated quantification of 23 benzodiazepines, flumazenil, zaleplone, zolpidem and zopiclone in plasma by liquid chromatography/mass spectrometry with atmospheric pressure chemical

# **Interpretation of Z drugs-Zaleplon, Zolpidem, Zopiclone Impairment Cases: What You Should Be Reading Bibliography**

ionization." J Mass Spectrom 39(8): 856-72.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=15329838](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15329838)

Kintz, P., M. Villain, et al. (2004). "Testing for the undetectable in drug-facilitated sexual assault using hair analyzed by tandem mass spectrometry as evidence." Ther Drug Monit 26(2): 211-4.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=15228167](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15228167)

Gunnar, T., S. Mykkanen, et al. (2004). "Validated semiquantitative/quantitative screening of 51 drugs in whole blood as silylated derivatives by gas chromatography-selected ion monitoring mass spectrometry and gas chromatography electron capture detection." J Chromatogr B Analyt Technol Biomed Life Sci 806(2): 205-19.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=15171931](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15171931)

Gouille, J. P. and J. P. Anger (2004). "Drug-facilitated robbery or sexual assault: problems associated with amnesia." Ther Drug Monit 26(2): 206-10.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=15228166](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15228166)

Dundar, Y., A. Boland, et al. (2004). "Newer hypnotic drugs for the short-term management of insomnia: a systematic review and economic evaluation." Health Technol Assess 8(24): iii-x, 1-125.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=15193209](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15193209)

Drover, D. R. (2004). "Comparative pharmacokinetics and pharmacodynamics of short-acting hypnotics: zaleplon, zolpidem and zopiclone." Clin Pharmacokinet 43(4): 227-38.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=15005637](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15005637)

Wang, J. S. and C. L. DeVane (2003). "Pharmacokinetics and drug interactions of the sedative hypnotics." Psychopharmacol Bull 37(1): 10-29.

# **Interpretation of Z drugs-Zaleplon, Zolpidem, Zopiclone Impairment Cases: What You Should Be Reading Bibliography**

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=14561946](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14561946)

Visser, S. A., F. L. Wolters, et al. (2003). "**Mechanism-based pharmacokinetic/pharmacodynamic modeling of the electroencephalogram effects of GABAA receptor modulators: in vitro-in vivo correlations.**" J Pharmacol Exp Ther 304(1): 88-101.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=12490579](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12490579)

Terzano, M. G., M. Rossi, et al. (2003). "**New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon.**" Drug Saf 26(4): 261-82.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=12608888](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12608888)

Stillwell, M. E. (2003). "**Zaleplon and driving impairment.**" J Forensic Sci 48(3): 677-9.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=12762547](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12762547)

Schaller, B. (2003). "**Zopiclone: some remarks on pharmacokinetics and pharmacodynamics.**" Swiss Med Wkly 133(5-6): 100.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=12644964](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12644964)

Reith, D. M., J. Fountain, et al. (2003). "**Comparison of the fatal toxicity index of zopiclone with benzodiazepines.**" J Toxicol Clin Toxicol 41(7): 975-80.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=14705844](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14705844)

Paul, M. A., G. Gray, et al. (2003). "**Impact of melatonin, zaleplon, zopiclone, and temazepam on psychomotor performance.**" Aviat Space Environ Med 74(12): 1263-70.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=14692469](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14692469)

## **Interpretation of Z drugs-Zaleplon, Zolpidem, Zopiclone Impairment Cases: What You Should Be Reading Bibliography**

Partinen, M., K. Hirvonen, et al. (2003). "Effects of after-midnight intake of zolpidem and temazepam on driving ability in women with non-organic insomnia." Sleep Med 4(6): 553-61.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=14607350](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14607350)

Olubodun, J. O., H. R. Ochs, et al. (2003). "Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men." Br J Clin Pharmacol 56(3): 297-304.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=12919178](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12919178)

Hesse, L. M., L. L. von Moltke, et al. (2003). "Clinically important drug interactions with zopiclone, zolpidem and zaleplon." CNS Drugs 17(7): 513-32.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=12751920](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12751920)

Hajak, G., W. E. Muller, et al. (2003). "Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data." Addiction 98(10): 1371-8.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=14519173](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14519173)

Estivill, E., A. Bove, et al. (2003). "Consensus on drug treatment, definition and diagnosis for insomnia." Clin Drug Investig 23(6): 351-85.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=17535048](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17535048)

Denise, P. and M. L. Bocca (2003). "Effects of zolpidem 10 mg, zopiclone 7.5 mg and flunitrazepam 1 mg on night-time motor activity." Eur Neuropsychopharmacol 13(2): 111-5.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=12650955](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12650955)

Berthelon, C., M. L. Bocca, et al. (2003). "Do zopiclone, zolpidem and flunitrazepam have residual effects on simulated task of collision anticipation?" J Psychopharmacol 17(3): 324-31.

# **Interpretation of Z drugs-Zaleplon, Zolpidem, Zopiclone Impairment Cases: What You Should Be Reading Bibliography**

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=14513925](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14513925)

Allain, H., D. Bentue-Ferrer, et al. (2003). "Effects on postural oscillation and memory functions of a single dose of zolpidem 5 mg, zopiclone 3.75 mg and lormetazepam 1 mg in elderly healthy subjects. A randomized, cross-over, double-blind study versus placebo." Eur J Clin Pharmacol 59(3): 179-88.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=12756510](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12756510)

Verster, J. C., E. R. Volkerts, et al. (2002). "Residual effects of middle-of-the-night administration of zaleplon and zolpidem on driving ability, memory functions, and psychomotor performance." J Clin Psychopharmacol 22(6): 576-83.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=12454557](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12454557)

Vermeeren, A., W. J. Riedel, et al. (2002). "Differential residual effects of zaleplon and zopiclone on actual driving: a comparison with a low dose of alcohol." Sleep 25(2): 224-31.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=11905433](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11905433)

Richardson, J. A., S. M. Gwaltney-Brant, et al. (2002). "Clinical syndrome associated with zolpidem ingestion in dogs: 33 cases (January 1998-July 2000)." J Vet Intern Med 16(2): 208-10.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=11899040](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11899040)

Renwick, A. B., S. E. Ball, et al. (2002). "Inhibition of zaleplon metabolism by cimetidine in the human liver: in vitro studies with subcellular fractions and precision-cut liver slices." Xenobiotica 32(10): 849-62.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=12419015](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12419015)

Olubodun, J. O., H. R. Ochs, et al. (2002). "Zolpidem pharmacokinetic properties in young females: influence of smoking and oral contraceptive

# **Interpretation of Z drugs-Zaleplon, Zolpidem, Zopiclone Impairment Cases: What You Should Be Reading Bibliography**

use." J Clin Pharmacol 42(10): 1142-6.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=12362929](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12362929)

Nordgren, H. K., K. Bodin, et al. (2002). "**Chromatographic screening for zopiclone and metabolites in urine using liquid chromatography and liquid chromatography-mass spectrometry techniques.**" Ther Drug Monit 24(3): 410-6.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=12021634](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12021634)

Lau, C. E., L. Sun, et al. (2002). "**The effect of zolpidem on operant behavior and its relation to pharmacokinetics after intravenous and subcutaneous administration: concentration-effect relations.**" Behav Pharmacol 13(2): 93-103.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=11981222](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11981222)

Lake, B. G., S. E. Ball, et al. (2002). "**Metabolism of zaleplon by human liver: evidence for involvement of aldehyde oxidase.**" Xenobiotica 32(10): 835-47.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=12419014](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12419014)

Kuntze, M. F., A. H. Bullinger, et al. (2002). "**Excessive use of zopiclone: a case report.**" Swiss Med Wkly 132(35-36): 523.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=12506335](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12506335)

Israel, A. G. and J. A. Kramer (2002). "**Safety of zaleplon in the treatment of insomnia.**" Ann Pharmacother 36(5): 852-9.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=11978165](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11978165)

Hirst, A. and R. Sloan (2002). "**Benzodiazepines and related drugs for insomnia in palliative care.**" Cochrane Database Syst Rev(4): CD003346.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=12519593](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12519593)

# **Interpretation of Z drugs-Zaleplon, Zolpidem, Zopiclone Impairment Cases: What You Should Be Reading Bibliography**

Grunstein, R. (2002). "Insomnia. Diagnosis and management." Aust Fam Physician 31(11): 995-1000.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=12471955](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12471955)

Fernandez, C., P. Alet, et al. (2002). "Stereoselective distribution and stereoconversion of zopiclone enantiomers in plasma and brain tissues in rats." J Pharm Pharmacol 54(3): 335-40.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=11902799](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11902799)

Rush, C. R. and R. W. Baker (2001). "Zolpidem and triazolam interact differentially with a delay interval on a digit-enter-and-recall task." Hum Psychopharmacol 16(2): 147-157.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=12404585](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12404585)

Roth, T., G. Hajak, et al. (2001). "Consensus for the pharmacological management of insomnia in the new millennium." Int J Clin Pract 55(1): 42-52.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=11219318](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11219318)

Patat, A., I. Paty, et al. (2001). "Pharmacodynamic profile of Zaleplon, a new non-benzodiazepine hypnotic agent." Hum Psychopharmacol 16(5): 369-392.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=12404558](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12404558)

Menzin, J., K. M. Lang, et al. (2001). "A general model of the effects of sleep medications on the risk and cost of motor vehicle accidents and its application to France." Pharmacoeconomics 19(1): 69-78.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=11252547](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11252547)

Mangano, R. M. (2001). "Efficacy and safety of zaleplon at peak plasma levels." Int J Clin Pract Suppl(116): 9-13.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=11252547](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11252547)

# Interpretation of Z drugs-Zaleplon, Zolpidem, Zopiclone Impairment Cases: What You Should Be Reading Bibliography

opt=Citation&list\_uids=11219331

Logan, B. K. and F. J. Couper (2001). "Zolpidem and driving impairment." J Forensic Sci 46(1): 105-10.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=11210892](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11210892)

Hindmarch, I., A. Patat, et al. (2001). "Residual effects of zaleplon and zolpidem following middle of the night administration five hours to one hour before awakening." Hum Psychopharmacol 16(2): 159-167.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=12404586](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12404586)

Hamad, A. and N. Sharma (2001). "Acute zolpidem overdose leading to coma and respiratory failure." Intensive Care Med 27(7): 1239.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=11534578](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11534578)

George, C. F. (2001). "Pyrazolopyrimidines." Lancet 358(9293): 1623-6.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=11716908](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11716908)

Brodeur, M. R. and A. L. Stirling (2001). "Delirium associated with zolpidem." Ann Pharmacother 35(12): 1562-4.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=11793620](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11793620)

Bramness, J. G., M. Arnestad, et al. (2001). "Fatal overdose of zopiclone in an elderly woman with bronchogenic carcinoma." J Forensic Sci 46(5): 1247-9.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=11569575](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11569575)

Bhatia, S. C., M. Arora, et al. (2001). "Perceptual disturbances with zaleplon." Psychiatr Serv 52(1): 109-10.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=11141544](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11141544)

Weitzel, K. W., J. M. Wickman, et al. (2000). "Zaleplon: a

# **Interpretation of Z drugs-Zaleplon, Zolpidem, Zopiclone Impairment Cases: What You Should Be Reading Bibliography**

**pyrazolopyrimidine sedative-hypnotic agent for the treatment of insomnia." Clin Ther 22(11): 1254-67.**

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=11117652](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11117652)

**Wagner, J. and M. L. Wagner (2000). "Non-benzodiazepines for the treatment of insomnia." Sleep Med Rev 4(6): 551-581.**

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=12531036](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12531036)

**Uchiumi, M., S. Isawa, et al. (2000). "The effects of zolpidem and zopiclone on daytime sleepiness and psychomotor performance." Nihon Shinkei Seishin Yakurigaku Zasshi 20(3): 123-30.**

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=11215153](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11215153)

**Troy, S. M., I. Lucki, et al. (2000). "Comparison of the effects of zaleplon, zolpidem, and triazolam on memory, learning, and psychomotor performance." J Clin Psychopharmacol 20(3): 328-37.**

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=10831020](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10831020)

**Nakajima, T., S. Takazawa, et al. (2000). "Effects of zolpidem and zopiclone on cognitive and attentional function in young healthy volunteers: an event-related potential study." Psychiatry Clin Neurosci 54(1): 37-40.**

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=15558877](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15558877)

**Mitler, M. M. (2000). "Nonselective and selective benzodiazepine receptor agonists--where are we today?" Sleep 23 Suppl 1: S39-47.**

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=10755807](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10755807)

**Isawa, S., M. Suzuki, et al. (2000). "The effect of zolpidem and zopiclone on memory." Nihon Shinkei Seishin Yakurigaku Zasshi 20(2): 61-9.**

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=11062863](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11062863)

# **Interpretation of Z drugs-Zaleplon, Zolpidem, Zopiclone Impairment Cases: What You Should Be Reading Bibliography**

Holm, K. J. and K. L. Goa (2000). "Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia."

Drugs 59(4): 865-89.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=10804040](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10804040)

Heydorn, W. E. (2000). "Zaleplon - a review of a novel sedative hypnotic used in the treatment of insomnia." Expert Opin Investig Drugs 9(4): 841-58.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=11060714](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11060714)

Hetta, J., J. E. Broman, et al. (2000). "Psychomotor effects of zaleplon and thioridazine coadministration." Eur J Clin Pharmacol 56(3): 211-7.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=10952475](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10952475)

Hedner, J., R. Yaeche, et al. (2000). "Zaleplon shortens subjective sleep latency and improves subjective sleep quality in elderly patients with insomnia. The Zaleplon Clinical Investigator Study Group." Int J Geriatr Psychiatry 15(8): 704-12.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=10960882](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10960882)

Freudenreich, O. and M. Menza (2000). "Zolpidem-related delirium: a case report." J Clin Psychiatry 61(6): 449-50.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=10901348](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10901348)

Drover, D., H. Lemmens, et al. (2000). "Pharmacokinetics, pharmacodynamics, and relative pharmacokinetic/pharmacodynamic profiles of zaleplon and zolpidem." Clin Ther 22(12): 1443-61.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=11192136](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11192136)

Dresser, G. K., J. D. Spence, et al. (2000). "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38(1): 41-57.

# **Interpretation of Z drugs-Zaleplon, Zolpidem, Zopiclone Impairment Cases: What You Should Be Reading Bibliography**

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=10668858](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10668858)

Drake, C. L., T. A. Roehrs, et al. (2000). **"Dose-response effects of zaleplon as compared with triazolam (0.25 mg) and placebo in chronic primary insomnia."** Hum Psychopharmacol 15(8): 595-604.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=12404612](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12404612)

Dooley, M. and G. L. Plosker (2000). **"Zaleplon: a review of its use in the treatment of insomnia."** Drugs 60(2): 413-45.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=10983740](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10983740)

Bocca, M. L. and P. Denise (2000). **"Residual effects of hypnotics on disengagement of spatial attention."** J Psychopharmacol 14(4): 401-5.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=11198059](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11198059)

Yoshimoto, M., H. Higuchi, et al. (1999). **"The effects of benzodiazepine (triazolam), cyclopyrrolone (zopiclone) and imidazopyridine (zolpidem) hypnotics on the frequency of hippocampal theta activity and sleep structure in rats."** Eur Neuropsychopharmacol 9(1-2): 29-35.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=10082225](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10082225)

Von Moltke, L. L., D. J. Greenblatt, et al. (1999). **"Zolpidem metabolism in vitro: responsible cytochromes, chemical inhibitors, and in vivo correlations."** Br J Clin Pharmacol 48(1): 89-97.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=10383565](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10383565)

Soldatos, C. R., D. G. Dikeos, et al. (1999). **"Tolerance and rebound insomnia with rapidly eliminated hypnotics: a meta-analysis of sleep laboratory studies."** Int Clin Psychopharmacol 14(5): 287-303.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=10529072](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10529072)

# **Interpretation of Z drugs-Zaleplon, Zolpidem, Zopiclone Impairment Cases: What You Should Be Reading Bibliography**

Sadeg, N., P. Deschamps, et al. (1999). "[Zolpidem intoxication]." Therapie 54(2): 264-7.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=10394268](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10394268)

Rush, C. R., J. M. Frey, et al. (1999). "Zaleplon and triazolam in humans: acute behavioral effects and abuse potential." Psychopharmacology (Berl) 145(1): 39-51.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=10445371](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10445371)

Rush, C. R., R. W. Baker, et al. (1999). "Acute behavioral effects and abuse potential of trazodone, zolpidem and triazolam in humans." Psychopharmacology (Berl) 144(3): 220-33.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=10435388](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10435388)

Rosen, A. S., P. Fournie, et al. (1999). "Zaleplon pharmacokinetics and absolute bioavailability." Biopharm Drug Dispos 20(3): 171-5.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=10211871](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10211871)

Levine, B., S. C. Wu, et al. (1999). "Zolpidem distribution in postmortem cases." J Forensic Sci 44(2): 369-71.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=10097364](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10097364)

Gock, S. B., S. H. Wong, et al. (1999). "Acute zolpidem overdose--report of two cases." J Anal Toxicol 23(6): 559-62.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=10517569](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10517569)

Chouinard, G., K. Lefko-Singh, et al. (1999). "Metabolism of anxiolytics and hypnotics: benzodiazepines, buspirone, zopiclone, and zolpidem." Cell Mol Neurobiol 19(4): 533-52.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=10379424](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10379424)

## **Interpretation of Z drugs-Zaleplon, Zolpidem, Zopiclone Impairment Cases: What You Should Be Reading Bibliography**

**Bocca, M. L., F. Le Doze, et al. (1999). "Residual effect of zolpidem 10 mg and zopiclone 7.5 mg versus flunitrazepam 1 mg and placebo on driving performance and ocular saccades." Psychopharmacology (Berl) 143(4): 373-9.**

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=10367554](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10367554)

**Rush, C. R. (1998). "Behavioral pharmacology of zolpidem relative to benzodiazepines: a review." Pharmacol Biochem Behav 61(3): 253-69.**

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=9768560](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9768560)

**Noble, S., H. D. Langtry, et al. (1998). "Zopiclone. An update of its pharmacology, clinical efficacy and tolerability in the treatment of insomnia." Drugs 55(2): 277-302.**

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=9506247](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9506247)

**Mattila, M. J., J. Vanakoski, et al. (1998). "Effects of alcohol, zolpidem, and some other sedatives and hypnotics on human performance and memory." Pharmacol Biochem Behav 59(4): 917-23.**

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=9586849](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9586849)

**Greenblatt, D. J., J. S. Harmatz, et al. (1998). "Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo." Clin Pharmacol Ther 64(5): 553-61.**

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=9834048](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9834048)

**Villikka, K., K. T. Kivisto, et al. (1997). "Rifampin reduces plasma concentrations and effects of zolpidem." Clin Pharmacol Ther 62(6): 629-34.**

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=9433391](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9433391)

**Villikka, K., K. T. Kivisto, et al. (1997). "Concentrations and effects of zopiclone are greatly reduced by rifampicin." Br J Clin Pharmacol 43(5):**

# **Interpretation of Z drugs-Zaleplon, Zolpidem, Zopiclone Impairment Cases: What You Should Be Reading Bibliography**

471-4.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=9159561](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9159561)

**Ptacek, P., J. Macek, et al. (1997). "Rapid and simple method for the determination of zolpidem in human plasma by high-performance liquid chromatography." J Chromatogr B Biomed Sci Appl 694(2): 409-13.**

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=9252056](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9252056)

**Pitner, J. K., M. Gardner, et al. (1997). "Zolpidem-induced psychosis in an older woman." J Am Geriatr Soc 45(4): 533-4.**

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=9100733](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9100733)

**Mannaert, E., J. Tytgat, et al. (1997). "Detection of 2-amino-5-chloropyridine in urine as a parameter of zopiclone (Imovane) intake using HPLC with diode array detection." J Anal Toxicol 21(3): 208-12.**

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=9171204](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9171204)

**Lobo, B. L. and W. L. Greene (1997). "Zolpidem: distinct from triazolam?" Ann Pharmacother 31(5): 625-32.**

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=9161660](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9161660)

**Lichtenwalner, M. and R. Tully (1997). "A fatality involving zolpidem." J Anal Toxicol 21(7): 567-9.**

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=9399127](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9399127)

**Durol, A. L. and D. J. Greenblatt (1997). "Analysis of zolpidem in human plasma by high-performance liquid chromatography with fluorescence detection: application to single-dose pharmacokinetic studies." J Anal Toxicol 21(5): 388-92.**

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=9288593](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9288593)

# **Interpretation of Z drugs-Zaleplon, Zolpidem, Zopiclone Impairment Cases: What You Should Be Reading Bibliography**

Wyss, P. A., D. Radovanovic, et al. (1996). "[**Acute overdose of Zolpidem (Stilnox)**]." Schweiz Med Wochenschr 126(18): 750-6.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=8693299](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8693299)

Winek, C. L., W. W. Wahba, et al. (1996). "**Acute overdose of zolpidem.**" Forensic Sci Int 78(3): 165-8.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=8635759](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8635759)

Stanke, F., N. Jourdil, et al. (1996). "**Simultaneous determination of zolpidem and zopiclone in human plasma by gas chromatography-nitrogen-phosphorus detection.**" J Chromatogr B Biomed Appl 675(1): 43-51.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=8634767](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8634767)

Rush, C. R. and R. R. Griffiths (1996). "**Zolpidem, triazolam, and temazepam: behavioral and subject-rated effects in normal volunteers.**" J Clin Psychopharmacol 16(2): 146-57.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=8690830](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8690830)

Luurila, H. and K. T. Olkkola (1996). "**Pharmacokinetic-pharmacodynamic modelling of zopiclone effects on human central nervous system.**" Pharmacol Toxicol 78(5): 348-53.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=8737972](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8737972)

Jalava, K. M., K. T. Olkkola, et al. (1996). "**Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zopiclone.**" Eur J Clin Pharmacol 51(3-4): 331-4.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=9010708](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9010708)

Hoyler, C. L., J. L. Tekell, et al. (1996). "**Zolpidem-induced agitation and disorganization.**" Gen Hosp Psychiatry 18(6): 452-3.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=8937915](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8937915)

# **Interpretation of Z drugs-Zaleplon, Zolpidem, Zopiclone Impairment Cases: What You Should Be Reading Bibliography**

Hempel, G. and G. Blaschke (1996). "Enantioselective determination of zopiclone and its metabolites in urine by capillary electrophoresis." J Chromatogr B Biomed Appl 675(1): 139-46.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=8634755](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8634755)

Boniface, P. J. and S. G. Russell (1996). "Two cases of fatal zopiclone overdose." J Anal Toxicol 20(2): 131-3.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=8868406](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8868406)

Wilkinson, C. J. (1995). "The acute effects of zolpidem, administered alone and with alcohol, on cognitive and psychomotor function." J Clin Psychiatry 56(7): 309-18.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=7615484](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=7615484)

Salva, P. and J. Costa (1995). "Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications." Clin Pharmacokinet 29(3): 142-53.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=8521677](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8521677)

Paut, O., J. L. Vercher, et al. (1995). "Evaluation of saccadic eye movements as an objective test of recovery from anaesthesia." Acta Anaesthesiol Scand 39(8): 1117-24.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=8607321](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8607321)

Mendelson, W. B. and B. Jain (1995). "An assessment of short-acting hypnotics." Drug Saf 13(4): 257-70.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=8573298](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8573298)

Meeker, J. E., C. W. Som, et al. (1995). "Zolpidem tissue concentrations in a multiple drug related death involving Ambien." J Anal Toxicol 19(6): 531-4.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=8926752](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8926752)

# **Interpretation of Z drugs-Zaleplon, Zolpidem, Zopiclone Impairment Cases: What You Should Be Reading Bibliography**

Fernandez, C., C. Martin, et al. (1995). "**Clinical pharmacokinetics of zopiclone.**" Clin Pharmacokinet 29(6): 431-41.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=8787948](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8787948)

Roehrs, T., L. Merlotti, et al. (1994). "**Sedative, memory, and performance effects of hypnotics.**" Psychopharmacology (Berl) 116(2): 130-4.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=7862941](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=7862941)

Pounder, D. J. and J. I. Davies (1994). "**Zopiclone poisoning: tissue distribution and potential for postmortem diffusion.**" Forensic Sci Int 65(3): 177-83.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=8039775](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8039775)

Patat, A., S. Trocherie, et al. (1994). "**EEG profile of intravenous zolpidem in healthy volunteers.**" Psychopharmacology (Berl) 114(1): 138-46.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=7846196](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=7846196)

Morgan, K. (1994). "**Hypnotic drugs, psychomotor performance and ageing.**" J Sleep Res 3(1): 1-15.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=10607103](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10607103)

Kuitunen, T. (1994). "**Drug and ethanol effects on the clinical test for drunkenness: single doses of ethanol, hypnotic drugs and antidepressant drugs.**" Pharmacol Toxicol 75(2): 91-8.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=7971743](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=7971743)

Hindmarch, I. and D. B. Fairweather (1994). "**Assessing the residual effects of hypnotics.**" Acta Psychiatr Belg 94(2): 88-95.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=7502663](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=7502663)

Garnier, R., E. Guerault, et al. (1994). "**Acute zolpidem poisoning--analysis**

# **Interpretation of Z drugs-Zaleplon, Zolpidem, Zopiclone Impairment Cases: What You Should Be Reading Bibliography**

**of 344 cases." J Toxicol Clin Toxicol 32(4): 391-404.**

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=8057398](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8057398)

**Aranko, K., H. Luurila, et al. (1994). "The effect of erythromycin on the pharmacokinetics and pharmacodynamics of zopiclone." Br J Clin Pharmacol 38(4): 363-7.**

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=7833227](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=7833227)

**Ahrens, B., H. Schutz, et al. (1994). "Screening, identification and determination of the two new hypnotics zolpidem and zopiclone." Arzneimittelforschung 44(7): 799-802.**

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=7945511](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=7945511)

**Wadworth, A. N. and D. McTavish (1993). "Zopiclone. A review of its pharmacological properties and therapeutic efficacy as an hypnotic." Drugs Aging 3(5): 441-59.**

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=8241608](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8241608)

**Kanno, O., H. Watanabe, et al. (1993). "Effects of zopiclone, flunitrazepam, triazolam and levomepromazine on the transient change in sleep-wake schedule: polygraphic study, and the evaluation of sleep and daytime condition." Prog Neuropsychopharmacol Biol Psychiatry 17(2): 229-39.**

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=8430216](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8430216)

**Hoehns, J. D. and P. J. Perry (1993). "Zolpidem: a nonbenzodiazepine hypnotic for treatment of insomnia." Clin Pharm 12(11): 814-28.**

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=8275648](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8275648)

**Fillastre, J. P., S. Geffroy-Josse, et al. (1993). "Pharmacokinetics and pharmacodynamics of zolpidem following repeated doses in hemodialyzed uraemic patients." Fundam Clin Pharmacol 7(1): 1-9.**

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=8275648](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8275648)

# **Interpretation of Z drugs-Zaleplon, Zolpidem, Zopiclone Impairment Cases: What You Should Be Reading Bibliography**

opt=Citation&list\_uids=8458597

**Fernandez, C., V. Maradeix, et al. (1993). "Pharmacokinetics of zopiclone and its enantiomers in Caucasian young healthy volunteers." Drug Metab Dispos 21(6): 1125-8.**

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=7905394](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=7905394)

**Berlin, I., D. Warot, et al. (1993). "Comparison of the effects of zolpidem and triazolam on memory functions, psychomotor performances, and postural sway in healthy subjects." J Clin Psychopharmacol 13(2): 100-6.**  
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=8463441](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8463441)

**Allen, D., H. V. Curran, et al. (1993). "The effects of single doses of CL284,846, lorazepam, and placebo on psychomotor and memory function in normal male volunteers." Eur J Clin Pharmacol 45(4): 313-20.**  
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=8299662](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8299662)

**Tafti, M., A. Besset, et al. (1992). "Effects of zopiclone on subjective evaluation of sleep and daytime alertness and on psychomotor and physical performance tests in athletes." Prog Neuropsychopharmacol Biol Psychiatry 16(1): 55-63.**  
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=1557507](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=1557507)

**Saano, V., P. P. Hansen, et al. (1992). "Interactions and comparative effects of zopiclone, diazepam and lorazepam on psychomotor performance and on elimination pharmacokinetics in healthy volunteers." Pharmacol Toxicol 70(2): 135-9.**  
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=1508840](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=1508840)

**Royer-Morrot, M. J., M. Rambourg, et al. (1992). "Determination of zopiclone in plasma using column liquid chromatography with ultraviolet detection." J Chromatogr 581(2): 297-9.**  
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=1508840](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=1508840)

# **Interpretation of Z drugs-Zaleplon, Zolpidem, Zopiclone Impairment Cases: What You Should Be Reading Bibliography**

opt=Citation&list\_uids=1452623

Jonas, J. M., B. S. Coleman, et al. (1992). "Comparative clinical profiles of triazolam versus other shorter-acting hypnotics." J Clin Psychiatry 53 Suppl: 19-31; discussion 32-3.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=1336776](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=1336776)

Durand, A., J. P. Thenot, et al. (1992). "Comparative pharmacokinetic profile of two imidazopyridine drugs: zolpidem and alpidem." Drug Metab Rev 24(2): 239-66.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=1576937](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=1576937)

Byrnes, J. J., D. J. Greenblatt, et al. (1992). "Benzodiazepine receptor binding of nonbenzodiazepines in vivo: alpidem, zolpidem and zopiclone." Brain Res Bull 29(6): 905-8.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=1361878](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=1361878)

Ascalone, V., L. Flaminio, et al. (1992). "Determination of zolpidem, a new sleep-inducing agent, and its metabolites in biological fluids: pharmacokinetics, drug metabolism and overdosing investigations in humans." J Chromatogr 581(2): 237-50.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=1452614](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=1452614)

Ansseau, M., W. Pitchot, et al. (1992). "Psychotic reactions to zolpidem." Lancet 339(8796): 809.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=1347827](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=1347827)

Tobler, I., D. J. Dijk, et al. (1991). "Effects on night-time motor activity and performance in the morning after midazolam intake during the night." Arzneimittelforschung 41(6): 581-3.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=1930343](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=1930343)

# **Interpretation of Z drugs-Zaleplon, Zolpidem, Zopiclone Impairment Cases: What You Should Be Reading Bibliography**

Hindmarch, I. (1991). "**Residual effects of hypnotics: an update.**" J Clin Psychiatry 52 Suppl: 14-5.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=2071566](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2071566)

Fernandez, C., B. Baune, et al. (1991). "**Determination of zopiclone enantiomers in plasma by liquid chromatography using a chiral cellulose carbamate column.**" J Chromatogr 572(1-2): 195-202.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=1818054](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=1818054)

Debruyne, D., J. Lacotte, et al. (1991). "**Determination of zolpidem and zopiclone in serum by capillary column gas chromatography.**" J Pharm Sci 80(1): 71-4.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=2013854](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2013854)

Viron, B., M. De Meyer, et al. (1990). "**Steady state pharmacokinetics of zopiclone during multiple oral dosing (7.5 mg nocte) in patients with severe chronic renal failure.**" Int Clin Psychopharmacol 5 Suppl 2: 95-104.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=2387982](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2387982)

Tyrer, P. (1990). "**Zopiclone.**" Br J Hosp Med 44(4): 264-5.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=2249101](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2249101)

Ponciano, E., F. Freitas, et al. (1990). "**A comparison of the efficacy, tolerance and residual effects of zopiclone, flurazepam and placebo in insomniac outpatients.**" Int Clin Psychopharmacol 5 Suppl 2: 69-77.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=2201731](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2201731)

Musch, B. and F. Maillard (1990). "**Zopiclone, the third generation hypnotic: a clinical overview.**" Int Clin Psychopharmacol 5 Suppl 2: 147-58.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=2201726](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2201726)

# **Interpretation of Z drugs-Zaleplon, Zolpidem, Zopiclone Impairment Cases: What You Should Be Reading Bibliography**

Moon, C. A., I. Hindmarch, et al. (1990). "The effect of zopiclone 7.5 mg on the sleep, mood and performance of shift workers." Int Clin Psychopharmacol 5 Suppl 2: 79-83.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=2201732](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2201732)

Lheureux, P., G. Debailleul, et al. (1990). "Zolpidem intoxication mimicking narcotic overdose: response to flumazenil." Hum Exp Toxicol 9(2): 105-7.  
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=2111156](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2111156)

Langtry, H. D. and P. Benfield (1990). "Zolpidem. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential." Drugs 40(2): 291-313.  
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=2226217](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2226217)

Kuitunen, T., M. J. Mattila, et al. (1990). "Actions of zopiclone and carbamazepine, alone and in combination, on human skilled performance in laboratory and clinical tests." Br J Clin Pharmacol 30(3): 453-61.  
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=2223424](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2223424)

Kuitunen, T., M. J. Mattila, et al. (1990). "Actions and interactions of hypnotics on human performance: single doses of zopiclone, triazolam and alcohol." Int Clin Psychopharmacol 5 Suppl 2: 115-30.  
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=2201724](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2201724)

Evans, S. M., F. R. Funderburk, et al. (1990). "Zolpidem and triazolam in humans: behavioral and subjective effects and abuse liability." J Pharmacol Exp Ther 255(3): 1246-55.  
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=2262904](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2262904)

Bensimon, G., J. Foret, et al. (1990). "Daytime wakefulness following a bedtime oral dose of zolpidem 20 mg, flunitrazepam 2 mg and placebo." Br J Clin Pharmacol 30(3): 463-9.

# **Interpretation of Z drugs-Zaleplon, Zolpidem, Zopiclone Impairment Cases: What You Should Be Reading Bibliography**

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=2223425](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2223425)

Wildschiodtz, G., J. O. Ovesen, et al. (1989). "[Zopiclone (imovane)- -a new sedative agent]." Ugeskr Laeger 151(8): 518-20.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=2922859](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2922859)

van der Kleijn, E. (1989). "Effects of zopiclone and temazepam on sleep, behaviour and mood during the day." Eur J Clin Pharmacol 36(3): 247-51.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=2744064](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2744064)

Koelega, H. S. (1989). "Benzodiazepines and vigilance performance: a review." Psychopharmacology (Berl) 98(2): 145-56.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=2569213](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2569213)

Garrigou-Gadenne, D., J. T. Burke, et al. (1989). "Pharmacokinetics, brain distribution and pharmaco-electrocorticographic profile of zolpidem, a new hypnotic, in the rat." J Pharmacol Exp Ther 248(3): 1283-8.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=2703975](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2703975)

Bergener, M., R. Gola, et al. (1989). "The influence of age-dependent pharmacokinetics on the pharmacodynamics of hypnotic drugs: comparison of two hypnotics with different half-lives." Int Psychogeriatr 1(1): 17-29.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=2490902](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2490902)

Sanger, D. J., G. Perrault, et al. (1987). "The behavioral profile of zolpidem, a novel hypnotic drug of imidazopyridine structure." Physiol Behav 41(3): 235-40.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=3324120](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=3324120)

Marc-Aurele, J., G. Caille, et al. (1987). "Comparison of zopiclone pharmacokinetics in patients with impaired renal function and normal

# **Interpretation of Z drugs-Zaleplon, Zolpidem, Zopiclone Impairment Cases: What You Should Be Reading Bibliography**

subjects. **Effect of hemodialysis.**" Sleep 10 Suppl 1: 22-6.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=3438644](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=3438644)

Gaillot, J., Y. Le Roux, et al. (1987). "**Critical factors for pharmacokinetics of zopiclone in the elderly and in patients with liver and renal insufficiency.**" Sleep 10 Suppl 1: 7-21.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=3438645](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=3438645)

Broadhurst, A. and R. C. Cushnaghan (1987). "**Residual effects of zopiclone (Imovane).**" Sleep 10 Suppl 1: 48-53.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=3326115](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=3326115)

Sanger, D. J. and B. Zivkovic (1986). "**The discriminative stimulus properties of zolpidem, a novel imidazopyridine hypnotic.**" Psychopharmacology (Berl) 89(3): 317-22.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=2873608](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2873608)

O'Hanlon, J. F. and E. R. Volkerts (1986). "**Hypnotics and actual driving performance.**" Acta Psychiatr Scand Suppl 332: 95-104.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=3554901](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=3554901)

Griffiths, A. N., G. Tedeschi, et al. (1986). "**The effects of repeated doses of temazepam and nitrazepam on several measures of human performance.**" Acta Psychiatr Scand Suppl 332: 119-26.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=2883819](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2883819)

Godtilbsen, O. B., D. Jerko, et al. (1986). "**Residual effect of single and repeated doses of midazolam and nitrazepam in relation to their plasma concentrations.**" Eur J Clin Pharmacol 29(5): 595-600.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=2937638](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2937638)

# **Interpretation of Z drugs-Zaleplon, Zolpidem, Zopiclone Impairment Cases: What You Should Be Reading Bibliography**

Goa, K. L. and R. C. Heel (1986). "Zopiclone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy as an hypnotic." Drugs 32(1): 48-65.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=2874974](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2874974)

Wehli, L., R. Knusel, et al. (1985). "Comparison of midazolam and triazolam for residual effects." Arzneimittelforschung 35(11): 1700-4.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=2936353](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2936353)

Roth, T. and T. Roehrs (1985). "Determinants of residual effects of hypnotics." Accid Anal Prev 17(4): 291-6.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=4096793](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=4096793)

Mattila, M. J., M. Mattila, et al. (1985). "Acute pharmacokinetic and pharmacodynamic comparison of two different formulations of temazepam." Med Biol 63(1): 21-7.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=2860283](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2860283)

Harrison, C., Z. Subhan, et al. (1985). "Residual effects of zopiclone and benzodiazepine hypnotics on psychomotor performance related to car driving." Drugs Exp Clin Res 11(12): 823-9.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=2873010](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2873010)

Aranko, K., M. J. Mattila, et al. (1985). "Psychomotor effects of alprazolam and diazepam during acute and subacute treatment, and during the follow-up phase." Acta Pharmacol Toxicol (Copenh) 56(5): 364-72.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=2863920](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2863920)

Willumeit, H. P., H. Ott, et al. (1984). "Simulated car driving as a useful technique for the determination of residual effects and alcohol interaction after short- and long-acting benzodiazepines."

Psychopharmacology Suppl 1: 182-92.

# **Interpretation of Z drugs-Zaleplon, Zolpidem, Zopiclone Impairment Cases: What You Should Be Reading Bibliography**

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=6147840](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=6147840)

Warburton, D. M. and K. Wesnes (1984). "A comparison of temazepam and flurazepam in terms of sleep quality and residual changes in activation and performance." Arzneimittelforschung 34(11): 1601-4.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=6151842](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=6151842)

Caille, G., P. du Souich, et al. (1984). "Pharmacokinetic and clinical parameters of zopiclone and trimipramine when administered simultaneously to volunteers." Biopharm Drug Dispos 5(2): 117-25.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=6743780](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=6743780)

Nicholson, A. N. and B. M. Stone (1983). "Zopiclone: sleep and performance studies in healthy man." Pharmacology 27 Suppl 2: 92-7.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=6669635](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=6669635)

Nicholson, A. N. and B. M. Stone (1983). "Imidazobenzodiazepines: sleep and performance studies in humans." J Clin Psychopharmacol 3(2): 72-5.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=6841664](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=6841664)

Krueger, H. and W. Muller-Limmroth (1983). "Residual effects of flurazepam and brotizolam on psychomotor performance." Br J Clin Pharmacol 16 Suppl 2: 347S-351S.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=6661380](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=6661380)

Gorenstein, C. and V. Gentil (1983). "Residual and acute effects of flurazepam and triazolam in normal subjects." Psychopharmacology (Berl) 80(4): 376-9.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=6137859](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=6137859)

Gaillot, J., D. Heusse, et al. (1983). "Pharmacokinetics and metabolism of

# **Interpretation of Z drugs-Zaleplon, Zolpidem, Zopiclone Impairment Cases: What You Should Be Reading Bibliography**

**zopiclone.**" Pharmacology 27 Suppl 2: 76-91.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=6669634](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=6669634)

**Borbely, A. A., M. Loepfe, et al. (1983). "Midazolam and triazolam: hypnotic action and residual effects after a single bedtime dose."**

Arzneimittelforschung 33(10): 1500-2.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=6140018](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=6140018)

**Nicholson, A. N. and B. M. Stone (1982). "Zopiclone: sleep and performance studies in healthy man."** Int Pharmacopsychiatry 17 Suppl 2: 92-7.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=7188378](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=7188378)

**Lader, M. and S. C. Denney (1982). "A double-blind study to establish the residual effects of zopiclone on performance in healthy volunteers."** Int Pharmacopsychiatry 17 Suppl 2: 98-108.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=7188379](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=7188379)

**Gaillot, J., D. Heusse, et al. (1982). "Pharmacokinetics and metabolism of zopiclone."** Int Pharmacopsychiatry 17 Suppl 2: 76-91.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=7188377](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=7188377)

**Nicholson, A. N. (1981). "The use of short- and long-acting hypnotics in clinical medicine."** Br J Clin Pharmacol 11 Suppl 1: 61S-69S.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=6133538](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=6133538)

**Seppala, K., K. Korttila, et al. (1976). "Residual effects and skills related to driving after a single oral administration of diazepam, medazepam or lorazepam."** Br J Clin Pharmacol 3(5): 831-41.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=9967](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9967)

**Interpretation of Z drugs-Zaleplon, Zolpidem,  
Zopiclone Impairment Cases: What You Should Be  
Reading Bibliography  
Books, Book chapters, Monographs:**

**Web Sites:**